{"id":"epirubicin-cyclophosphamide-docetaxel-lapatinib","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Myelosuppression"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-20%","effect":"Anemia"},{"rate":"5-15%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea and vomiting"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Epirubicin, cyclophosphamide, and docetaxel work synergistically to induce apoptosis in rapidly dividing cancer cells. Lapatinib targets the HER2 and EGFR receptors, which are often overexpressed in certain types of cancer, further inhibiting tumor growth.","oneSentence":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 and EGFR receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:15.837Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic breast cancer"},{"name":"Adjuvant treatment of node-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT00841828","phase":"PHASE2","title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2009-02","conditions":"Breast Cancer","enrollment":102},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT00567554","phase":"PHASE3","title":"Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2007-10","conditions":"Breast Cancer","enrollment":2600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"epirubicin - cyclophosphamide / docetaxel + lapatinib","genericName":"epirubicin - cyclophosphamide / docetaxel + lapatinib","companyName":"GBG Forschungs GmbH","companyId":"gbg-forschungs-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Epirubicin is an anthracycline antibiotic that intercalates DNA strands, inhibiting topoisomerase II and inducing apoptosis. Cyclophosphamide is an alkylating agent that cross-links DNA, causing cell death. Docetaxel is a taxane that stabilizes microtubules, preventing cell division. Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 and EGFR receptors. Used for Advanced or metastatic breast cancer, Adjuvant treatment of node-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}